

Symposium Program on Dose Selection for Cancer Treatments: May 12, 2017

Speaker: Ling Wang, Ph.D.
Associate Director of Biostatistics
Takeda Pharmaceuticals

Title: ***Combination dose finding studies in oncology: an industry perspective***

Abstract:

In the past decade, the number of dose finding studies in oncology has increased very significantly, with better understanding of the pre-clinical activities and the biological targets of the drugs. In this presentation, I will give an overview of the combination dose finding designs available and share some work on comparison of model based design such as Bayesian logistic regression model with rule based design. Then I will provide some perspectives on considerations of designs and other aspects from an industry point of view.